Rocket Pharmaceuticals, Inc.
- Home
- Companies
- Rocket Pharmaceuticals, Inc.
- Products
- Infantile Malignant Osteopetrosis (IMO)
Infantile Malignant Osteopetrosis (IMO)
In January 2022, Rocket disclosed plans return the program back to academic collaborators in order to reallocate resources to Rocket’s pipeline.
